Novel endpoints and design of early clinical trials
- 1 October 2002
- journal article
- review article
- Published by Elsevier in Annals of Oncology
- Vol. 13 (suppl_4) , 139-143
- https://doi.org/10.1093/annonc/mdf651
Abstract
W. R. Parulekar, E. A. Eisenhauer; Novel endpoints and design of early clinical trials, Annals of Oncology, Volume 13, Issue suppl_4, 1 October 2002, Pages 139Keywords
This publication has 15 references indexed in Scilit:
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Application of a New Multinomial Phase II Stopping Rule Using Response and Early ProgressionJournal of Clinical Oncology, 2001
- A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumoursAnnals of Oncology, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Development of Target-Based Antineoplastic AgentsInvestigational New Drugs, 2000
- Phase I and Pharmacologic Study of the Specific Matrix Metalloproteinase Inhibitor BAY 12-9566 on a Protracted Oral Daily Dosing Schedule in Patients With Solid MalignanciesJournal of Clinical Oncology, 2000
- Matrix Metalloproteinase Inhibitor DrugsEmerging Drugs, 1997
- Suramin-Induced Decrease in Prostate-Specific Antigen Expression With No Effect on Tumor Growth in the LNCaP Model of Human Prostate CancerJNCI Journal of the National Cancer Institute, 1996
- Matrix Metalloproteinases and Their Inhibitors in Tumor ProgressionaAnnals of the New York Academy of Sciences, 1994
- Regulation of Matrix Metalloproteinase ActivityaAnnals of the New York Academy of Sciences, 1994